| Product NDC: | 0173-0947 |
| Proprietary Name: | WELLBUTRIN |
| Non Proprietary Name: | bupropion hydrochloride |
| Active Ingredient(s): | 100 mg/1 & nbsp; bupropion hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0173-0947 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020358 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19961115 |
| Package NDC: | 0173-0947-55 |
| Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (0173-0947-55) |
| NDC Code | 0173-0947-55 |
| Proprietary Name | WELLBUTRIN |
| Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (0173-0947-55) |
| Product NDC | 0173-0947 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | bupropion hydrochloride |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 19961115 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | BUPROPION HYDROCHLORIDE |
| Strength Number | 100 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |